- Medical School - UT Southwestern Medical School (1999-2003)
- Residency - UT Southwestern Medical Center (2003-2006), Internal Medicine
- Fellowship - UT MD Anderson Cancer Center (2007-2010), Hematology Oncology
Suzanne Cole, M.D.
- Internal Medicine - Hematology/Oncology
- General Hematology/Oncology
Suzanne Cole, M.D., is a medical oncologist at UT Southwestern Medical Center. She serves as the Medical Director of the University Hospital Simmons Cancer Clinic at the UT Southwestern Medical Center at Richardson/Plano.
Dr. Cole earned her medical degree at UT Southwestern, where she also completed her residency in internal medicine. She then received advanced training in hematology and medical oncology through a fellowship at the University of Texas MD Anderson Cancer Center in Houston.
Dr. Cole spent eight years caring for patients in their local communities before she joined the UT Southwestern faculty in 2018.
Board certified in hematology and oncology, Dr. Cole is a Fellow of the American College of Physicians. She is active in a number of cancer-related professional organizations, including the American Society of Clinical Oncology and the American Society of Hematology, and she previously served on the board of the Oklahoma Society of Clinical Oncology. She is the founder of the Hematology & Oncology Women Physician Group.
Dr. Cole has delivered presentations throughout the nation and published articles in peer-reviewed journals covering topics related to cancer and blood-related disorders.
Meet Dr. Cole
Medical Oncologist and Hematologist in Dallas
Suzanne Cole, M.D., is a medical oncologist at UT Southwestern Medical Center and the Director of the University Hospital Simmons Cancer Clinic at the UT Southwestern Medical Center at Richardson/Plano. She and her team provide compassionate care for patients with cancer and blood-related disorders in a welcoming, community clinic.
Throughout her career, Dr. Cole has cared for cancer and hematology patients. With cancer in particular, she says, it’s vital for patients to fully trust their physicians.
“With cancer treatment, you’re putting your life into the hands of that care team,” she says. “There should be a human connection between the patient and the oncologist. A foundation of trust is essential. Each patient needs guidance that comes with honesty, empathy, and compassion.”
Dr. Cole proudly brings that level of care to each and every patient at the Richardson/Plano clinic. Her goal is to deliver UT Southwestern’s exceptional standard of care to the northern suburbs, giving cancer and hematology patients a convenient location to receive their chemotherapy or immunotherapy infusions and other medical treatments.
“Truly a Calling”
Dr. Cole recognizes that oncology and hematology can be challenging fields that aren’t necessarily a good fit for every physician. But ever since her medical training, she’s known that this was the type of work she was meant to do.
“This specialty is truly a calling,” she says. “And there is nothing I would rather do with my time than dedicate my life to finding a way to help people stay alive in the face of this life-threatening disease. I find such great honor in doing this important work. It really is a matter of life and death for my patients – and a matter of finding their way to a good life while going through cancer treatment. I see myself as a soldier in the trenches, walking with my patients, guiding them, fighting for them in their daily battles.”
Dr. Cole and her team work closely with patients to ensure the best treatment for each individual’s specific circumstances. She says for some it means finding a path for the patient to survive cancer; for others, the goal is to help patients endure treatment or live longer and maintain as much quality of life as possible in the face of terminal cancer.
Although for most patients a cancer diagnosis is a life-changing event, Dr. Cole and her team work to make it manageable – not only through compassionate, patient-centered care, but also by providing the best of what UT Southwestern has to offer: some of the leading physician scientists in medicine, the most cutting-edge technology, and the latest cancer research.
Dr. Cole is encouraged to see emerging cancer treatments, such as immunotherapy, that are revolutionizing cancer care. As a strong advocate of oncology research, she is always looking for ways to advance the field. One way she does this is by encouraging her patients to participate in clinical trials, which provide access to new and emerging treatments that could prove to be life-saving.
“Cancer research is crucial to moving a deadly disease toward a survivable one,” she says. “Improving access to and enrollment of patients into cancer clinical trials is vital to finding a path to a cure. I was shocked to learn that in the United States less than 5 percent of cancer patients enroll in clinical trials. Clinical trials often provide access to the latest and most promising breakthrough medications that ultimately go on to improve survival from this deadly disease.”
Dr. Cole says one of the reasons that so few patients participate in clinical trials is that they are often conducted in large medical universities, while most cancer patients receive their cancer care close to home in smaller hospital or clinic settings without access to research. However, she’s looking to change that for her patients in North Dallas.
“One of the great joys and passions in my career has been building programs to expand access to allow patients to participate in clinical trials in the local clinic facilities where they receive care,” she says. “If you have cancer, you should not be denied access to a potentially life-saving clinical trial just because you live two hours away.”
For patients in north Dallas, this is just one of the ways Dr. Cole is working to make her clinic a convenient location for high-quality care while also acting as a partner and advocate for each patient who walks through her door.
The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME, Future oncology (London, England) 2019 May 15 15 1683-1695
Impact of Closed Facebook Group Participation on Female Hematology/Oncology Physicians.
Graff SL, Close J, Cole S, Matt-Amaral L, Beg R, Markham MJ, Journal of oncology practice 2018 12 14 12 e758-e769
Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma.
Efebera YA, Qureshi SR, Cole SM, Saliba R, Pelosini M, Patel RM, Koca E, Mendoza FL, Wang M, Shah J, Alousi A, Hosing C, Popat U, Kebriaei P, Anderlini P, Khouri IF, Champlin R, Giralt S, Qazilbash MH Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2010 Aug 16 8 1122-9
Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature.
Cole S, Kantarjian H, Ault P, Cortés JE, Clinical lymphoma & myeloma 2009 Aug 9 4 324-7
An integrated (2)H and (13)C NMR study of gluconeogenesis and TCA cycle flux in humans.
Jones JG, Solomon MA, Cole SM, Sherry AD, Malloy CR American journal of physiology. Endocrinology and metabolism 2001 Oct 281 4 E848-56
Managing Immuno-Oncology Toxicity: Top 10 Innovative Institutional Solutions.
Cole S, Zibelman M, Bertino E, Yucebay F, Reynolds K, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2019 Jan 39 96-104
- The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?
- General Hematology/Oncology
Q&A by Dr. Cole
Showing 2 locations
Dallas, Texas 75390 214-645-4673